Cargando…
Safety of Four COVID-19 Vaccines across Primary Doses 1, 2, 3 and Booster: A Prospective Cohort Study of Australian Community Pharmacy Vaccinations
Four COVID-19 vaccines are approved for use in Australia: Pfizer-BioNTech BNT162b2 (Comirnaty), AstraZeneca ChAdOx1 (Vaxzevria), Moderna mRNA-1273 (Spikevax) and Novavax NVX-CoV2373 (Nuvaxovid). We sought to examine adverse events following immunisation (AEFI) at days 3 and 42 after primary doses 1,...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9786585/ https://www.ncbi.nlm.nih.gov/pubmed/36560426 http://dx.doi.org/10.3390/vaccines10122017 |
_version_ | 1784858321097850880 |
---|---|
author | Salter, Sandra M. Li, Dani Trentino, Kevin Nissen, Lisa Lee, Kenneth Orlemann, Karin Peters, Ian Murray, Kevin Leeb, Alan Deng, Lucy |
author_facet | Salter, Sandra M. Li, Dani Trentino, Kevin Nissen, Lisa Lee, Kenneth Orlemann, Karin Peters, Ian Murray, Kevin Leeb, Alan Deng, Lucy |
author_sort | Salter, Sandra M. |
collection | PubMed |
description | Four COVID-19 vaccines are approved for use in Australia: Pfizer-BioNTech BNT162b2 (Comirnaty), AstraZeneca ChAdOx1 (Vaxzevria), Moderna mRNA-1273 (Spikevax) and Novavax NVX-CoV2373 (Nuvaxovid). We sought to examine adverse events following immunisation (AEFI) at days 3 and 42 after primary doses 1, 2, 3 and booster. We conducted active vaccine safety surveillance from 130 community pharmacies in Australia integrated with AusVaxSafety, between August 2021–April 2022. Main outcomes: AEFI at 0–3 days post-vaccination; medical review/advice at 3 days and 42 days post-vaccination; SARS-CoV-2 breakthrough infection by day 42. Of 110,024 completed day 3 surveys (43.6% response rate), 50,367 (45.8%) reported any AEFI (highest proportions: Pfizer 42%, primary dose 3; AstraZeneca 58.3%, primary dose 1; Moderna 65.4% and Novavax 58.8%, both primary dose 2). The most common AEFI reported across all doses/vaccines were local reactions, systemic aches and fatigue/tiredness. Overall, 2172/110,024 (2.0%) and 1182/55,329 (2.1%) respondents sought medical review at days 3 and 42, respectively, and 931/42,318 (2.2%) reported breakthrough SARS-CoV-2 infection at day 42. We identified similar AEFI profiles but at lower proportions than previously reported for Pfizer, AstraZeneca, Moderna and Novavax COVID-19 vaccines. Moderna vaccine was the most reactogenic and associated with higher AEFI proportions across primary doses 2, 3, and booster. |
format | Online Article Text |
id | pubmed-9786585 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-97865852022-12-24 Safety of Four COVID-19 Vaccines across Primary Doses 1, 2, 3 and Booster: A Prospective Cohort Study of Australian Community Pharmacy Vaccinations Salter, Sandra M. Li, Dani Trentino, Kevin Nissen, Lisa Lee, Kenneth Orlemann, Karin Peters, Ian Murray, Kevin Leeb, Alan Deng, Lucy Vaccines (Basel) Article Four COVID-19 vaccines are approved for use in Australia: Pfizer-BioNTech BNT162b2 (Comirnaty), AstraZeneca ChAdOx1 (Vaxzevria), Moderna mRNA-1273 (Spikevax) and Novavax NVX-CoV2373 (Nuvaxovid). We sought to examine adverse events following immunisation (AEFI) at days 3 and 42 after primary doses 1, 2, 3 and booster. We conducted active vaccine safety surveillance from 130 community pharmacies in Australia integrated with AusVaxSafety, between August 2021–April 2022. Main outcomes: AEFI at 0–3 days post-vaccination; medical review/advice at 3 days and 42 days post-vaccination; SARS-CoV-2 breakthrough infection by day 42. Of 110,024 completed day 3 surveys (43.6% response rate), 50,367 (45.8%) reported any AEFI (highest proportions: Pfizer 42%, primary dose 3; AstraZeneca 58.3%, primary dose 1; Moderna 65.4% and Novavax 58.8%, both primary dose 2). The most common AEFI reported across all doses/vaccines were local reactions, systemic aches and fatigue/tiredness. Overall, 2172/110,024 (2.0%) and 1182/55,329 (2.1%) respondents sought medical review at days 3 and 42, respectively, and 931/42,318 (2.2%) reported breakthrough SARS-CoV-2 infection at day 42. We identified similar AEFI profiles but at lower proportions than previously reported for Pfizer, AstraZeneca, Moderna and Novavax COVID-19 vaccines. Moderna vaccine was the most reactogenic and associated with higher AEFI proportions across primary doses 2, 3, and booster. MDPI 2022-11-25 /pmc/articles/PMC9786585/ /pubmed/36560426 http://dx.doi.org/10.3390/vaccines10122017 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Salter, Sandra M. Li, Dani Trentino, Kevin Nissen, Lisa Lee, Kenneth Orlemann, Karin Peters, Ian Murray, Kevin Leeb, Alan Deng, Lucy Safety of Four COVID-19 Vaccines across Primary Doses 1, 2, 3 and Booster: A Prospective Cohort Study of Australian Community Pharmacy Vaccinations |
title | Safety of Four COVID-19 Vaccines across Primary Doses 1, 2, 3 and Booster: A Prospective Cohort Study of Australian Community Pharmacy Vaccinations |
title_full | Safety of Four COVID-19 Vaccines across Primary Doses 1, 2, 3 and Booster: A Prospective Cohort Study of Australian Community Pharmacy Vaccinations |
title_fullStr | Safety of Four COVID-19 Vaccines across Primary Doses 1, 2, 3 and Booster: A Prospective Cohort Study of Australian Community Pharmacy Vaccinations |
title_full_unstemmed | Safety of Four COVID-19 Vaccines across Primary Doses 1, 2, 3 and Booster: A Prospective Cohort Study of Australian Community Pharmacy Vaccinations |
title_short | Safety of Four COVID-19 Vaccines across Primary Doses 1, 2, 3 and Booster: A Prospective Cohort Study of Australian Community Pharmacy Vaccinations |
title_sort | safety of four covid-19 vaccines across primary doses 1, 2, 3 and booster: a prospective cohort study of australian community pharmacy vaccinations |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9786585/ https://www.ncbi.nlm.nih.gov/pubmed/36560426 http://dx.doi.org/10.3390/vaccines10122017 |
work_keys_str_mv | AT saltersandram safetyoffourcovid19vaccinesacrossprimarydoses123andboosteraprospectivecohortstudyofaustraliancommunitypharmacyvaccinations AT lidani safetyoffourcovid19vaccinesacrossprimarydoses123andboosteraprospectivecohortstudyofaustraliancommunitypharmacyvaccinations AT trentinokevin safetyoffourcovid19vaccinesacrossprimarydoses123andboosteraprospectivecohortstudyofaustraliancommunitypharmacyvaccinations AT nissenlisa safetyoffourcovid19vaccinesacrossprimarydoses123andboosteraprospectivecohortstudyofaustraliancommunitypharmacyvaccinations AT leekenneth safetyoffourcovid19vaccinesacrossprimarydoses123andboosteraprospectivecohortstudyofaustraliancommunitypharmacyvaccinations AT orlemannkarin safetyoffourcovid19vaccinesacrossprimarydoses123andboosteraprospectivecohortstudyofaustraliancommunitypharmacyvaccinations AT petersian safetyoffourcovid19vaccinesacrossprimarydoses123andboosteraprospectivecohortstudyofaustraliancommunitypharmacyvaccinations AT murraykevin safetyoffourcovid19vaccinesacrossprimarydoses123andboosteraprospectivecohortstudyofaustraliancommunitypharmacyvaccinations AT leebalan safetyoffourcovid19vaccinesacrossprimarydoses123andboosteraprospectivecohortstudyofaustraliancommunitypharmacyvaccinations AT denglucy safetyoffourcovid19vaccinesacrossprimarydoses123andboosteraprospectivecohortstudyofaustraliancommunitypharmacyvaccinations |